Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-11-2019 | Metastasis | Original Article – Clinical Oncology

Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series

Authors: Wanpeng Li, Hanyu Lu, Dehui Wang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2019

Abstract

Background

The purpose of this study was to explore the demographics, multimodality therapeutic outcomes*** and prognostic factors in sinonasal rhabdomyosarcoma (SNRMS).

Methods

We conducted a retrospective analysis of 40 patients who underwent treatment of SNRMS from March 2007 to March 2018. The Kaplan–Meier method and the log-rank test were used to assess survival rates. The Cox regression model was used for multivariate survival analysis.

Results

In total, 25 males and 15 females were included in the study; the median age was 33 years (range, 2–67 years). All patients underwent surgical resection, and surgery prior to or after adjuvant therapy (chemotherapy and radiotherapy) was performed in 91.4% of the patients. The overall 1-, 3- and 5-year survival rates were 77.0%, 46.5% and 46.5%, respectively, during a mean follow-up time of 27.9 (range, 2–128) months in all patients. The log-rank test showed Intergroup Rhabdomyosarcoma Study (IRS) group and infiltration of the skull base influenced overall survival (p = 0.001; p = 0.022). Advanced IRS stage, lymph node metastasis and tumor size ≥ 5 cm were also associated with an unfavorable outcome on overall survival (p = 0.01; p = 0.035; p = 0.02). The results of multivariate regression analysis showed patients with IRS group I were associated with better prognosis outcome on overall survival.

Conclusion

Patients with SNRMS have poor 5-year overall survival, and IRS group is the independent prognostic factor for overall survival.

Callender TA, Weber RS, Janjan N, Benjamin R, Zaher M, Wolf P, El-Naggar A (1995) Rhabdomyosarcoma of the nose and paranasal sinuses in adults and children. Otolaryngol Head Neck Surg 112:252–257. https://doi.org/10.1016/S0194-59989570246-6 CrossRefPubMed

Casey DL, Wolden SL (2018) Rhabdomyosarcoma of the Head and Neck: a Multimodal Approach. J Neurol Surg B Skull Base 79:58–64. https://doi.org/10.1055/s-0037-1617450 CrossRefPubMedPubMedCentral

Choi PJ, Iwanaga J, Tubbs RS, Yilmaz E (2018) Surgical interventions for advanced parameningeal rhabdomyosarcoma of children and adolescents. Cureus 10:e2045. https://doi.org/10.7759/cureus.2045 CrossRefPubMedPubMedCentral

Daya H, Chan HS, Sirkin W, Forte V (2000) Pediatric rhabdomyosarcoma of the head and neck: is there a place for surgical management? Arch Otolaryngol Head Neck Surg 126:468–472CrossRef

Ferrari A et al (2003) Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98:571–580. https://doi.org/10.1002/cncr.11550 CrossRefPubMed

Fyrmpas G, Wurm J, Athanassiadou F, Papageorgiou T, Beck JD, Iro H, Constantinidis J (2009) Management of paediatric sinonasal rhabdomyosarcoma. J Laryngol Otol 123:990–996. https://doi.org/10.1017/S0022215109005337 CrossRefPubMed

Gerber NK et al (2013) Adult rhabdomyosarcoma survival improved with treatment on multimodality protocols. Int J Radiat Oncol Biol Phys 86:58–63. https://doi.org/10.1016/j.ijrobp.2012.12.016 CrossRefPubMedPubMedCentral

Haussler SM, Stromberger C, Olze H, Seifert G, Knopke S, Bottcher A (2018) Head and neck rhabdomyosarcoma in children: a 20-year retrospective study at a tertiary referral center. J Cancer Res Clin Oncol 144:371–379. https://doi.org/10.1007/s00432-017-2544-x CrossRefPubMed

Healy GB, Upton J, Black PM, Ferraro N (1991) The role of surgery in rhabdomyosarcoma of the head and neck in children. Arch Otolaryngol Head Neck Surg 117:1185–1188CrossRef

Hicks J, Flaitz C (2002) Rhabdomyosarcoma of the head and neck in children. Oral Oncol 38:450–459CrossRef

Ognjanovic S, Linabery AM, Charbonneau B, Ross JA (2009) Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer 115:4218–4226. https://doi.org/10.1002/cncr.24465 CrossRefPubMedPubMedCentral

Orbach D et al (2017) Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. Head Neck 39:24–31. https://doi.org/10.1002/hed.24547 CrossRefPubMed

Raney RB et al (2001) The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 5:9–15. https://doi.org/10.1080/13577140120048890 CrossRefPubMedPubMedCentral

Rekhi B, Singhvi T (2014) Histopathological, immunohistochemical and molecular cytogenetic analysis of 21 spindle cell/sclerosing rhabdomyosarcomas. APMIS 122:1144–1152. https://doi.org/10.1111/apm.12272 CrossRefPubMed

Sanghvi S, Misra P, Patel NR, Kalyoussef E, Baredes S, Eloy JA (2013) Incidence trends and long-term survival analysis of sinonasal rhabdomyosarcoma. Am J Otolaryngol 34:682–689. https://doi.org/10.1016/j.amjoto.2013.04.012 CrossRefPubMed

Siddiqui SH et al (2019) Clinicopathologic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma. Int Forum Allergy Rhinol 9:363–369. https://doi.org/10.1002/alr.22267 CrossRefPubMed

Skapek SX et al (2013) PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children’s oncology group report. Pediatr Blood Cancer 60:1411–1417. https://doi.org/10.1002/pbc.24532 CrossRefPubMedPubMedCentral

Stepan K et al (2017) Outcomes in adult sinonasal rhabdomyosarcoma. Otolaryngol Head Neck Surg 157:135–141. https://doi.org/10.1177/0194599817696287 CrossRefPubMed

Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A (2009) Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2600 patients. J Clin Oncol 27:3391–3397. https://doi.org/10.1200/jco.2008.19.7483 CrossRefPubMed

Tsai JW et al (2019) The expanding morphological and genetic spectrum of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcomas: a clinicopathological and molecular comparison of mutated and non-mutated cases. Histopathology 74:933–943. https://doi.org/10.1111/his.13819 CrossRefPubMed

Turner JH, Richmon JD (2011) Head and neck rhabdomyosarcoma: a critical analysis of population-based incidence and survival data. Otolaryngol Head Neck Surg 145:967–973. https://doi.org/10.1177/0194599811417063 CrossRefPubMed

Unsal AA, Chung SY, Unsal AB, Baredes S, Eloy JA (2017) A population-based analysis of survival for sinonasal rhabdomyosarcoma. Otolaryngol Head Neck Surg 157:142–149. https://doi.org/10.1177/0194599817696292 CrossRefPubMed

Wharam MD Jr (1997) Rhabdomyosarcoma of Parameningeal Sites. Semin Radiat Oncol 7:212–216. https://doi.org/10.1053/SRAO00700212 CrossRefPubMed

Wu Y, Li C, Zhong Y, Guo W, Ren G (2014) Head and neck rhabdomyosarcoma in adults. J Craniofac Surg 25:922–925. https://doi.org/10.1097/SCS.0000000000000704 CrossRefPubMed

Wurm J, Constantinidis J, Grabenbauer GG, Iro H (2005) Rhabdomyosarcomas of the nose and paranasal sinuses: treatment results in 15 cases. Otolaryngol Head Neck Surg 133:42–50. https://doi.org/10.1016/j.otohns.2005.03.023 CrossRefPubMed

Title: Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series
Authors: Wanpeng Li
Hanyu Lu
Dehui Wang
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Rhabdomyosarcoma
Radiotherapy
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2019
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-03009-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2019

Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells

CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt/ERK/STAT3 pathways: novel therapeutic approach

Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China

Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer

Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype

Impact of 9q deletions on the classification of patients with acute myeloid leukemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page